{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:06:16Z","timestamp":1783926376723,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.119071","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:20:11Z","timestamp":1781626811000},"page":"119071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of potent Type-II GSK-3\u03b2\/VEGFR2 inhibitors with promising potential against tongue squamous cell carcinoma"],"prefix":"10.1016","volume":"316","author":[{"given":"Zihao","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongle","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruitao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longqian","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingde","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119071_bib1","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.119071_bib2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.14639\/0392-100X-N2055","article-title":"Oral tongue carcinoma: prognostic changes according to the updated 2020 version of the AJCC\/UICC TNM staging system","volume":"42","author":"Tagliabue","year":"2022","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"10.1016\/j.ejmech.2026.119071_bib3","first-page":"12","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.119071_bib4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.oraloncology.2017.02.015","article-title":"MicroRNAs in human tongue squamous cell carcinoma: from pathogenesis to therapeutic implications","volume":"67","author":"Karatas","year":"2017","journal-title":"Oral Oncol."},{"key":"10.1016\/j.ejmech.2026.119071_bib5","first-page":"5681","article-title":"Surgical treatment of early tongue squamous cell carcinoma and patient survival","volume":"17","author":"Zhu","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejmech.2026.119071_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41368-024-00343-7","article-title":"Tongue squamous cell carcinoma-targeting Au-HN-1 nanosystem for CT imaging and photothermal therapy","volume":"17","author":"Hao","year":"2025","journal-title":"Int. J. Oral Sci."},{"key":"10.1016\/j.ejmech.2026.119071_bib7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1432-1033.1980.tb06059.x","article-title":"Glycogen-Synthase Kinase-3 from rabbit skeletal-muscle - separation from cyclic-amp-dependent protein-kinase and phosphorylase-kinase","volume":"107","author":"Embi","year":"1980","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2026.119071_bib8","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/med.21867","article-title":"Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases","volume":"42","author":"Wang","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.119071_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116377","article-title":"Glycogen synthase kinase-3: a potential immunotherapeutic target in tumor microenvironment","volume":"173","author":"Liang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.119071_bib10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fnmol.2011.00040","article-title":"GSK-3: functional insights from cell biology and animal models","volume":"4","author":"Kaidanovich-Beilin","year":"2011","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ejmech.2026.119071_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115496","article-title":"GSK-3beta: an exuberating neuroinflammatory mediator in Parkinson's disease","volume":"210","author":"Samim Khan","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119071_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116065","article-title":"Targeting glycogen synthase kinase-3beta for Alzheimer's disease: recent advances and future prospects","volume":"265","author":"Cheng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119071_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.127375","article-title":"A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies","volume":"253","author":"Thapa","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2026.119071_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117204","article-title":"A review of developments in glycogen synthase kinase-3 regulators over the past 10 years","volume":"242","author":"Wang","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119071_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109053","article-title":"Small-molecule inhibitors of GSK3\u03b2: therapeutic potential and structure-activity relationship in multiple systems","volume":"165","author":"Wang","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119071_bib16","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1016\/j.bmcl.2011.06.050","article-title":"Identification of 2-(4-pyridyl)thienopyridinones as GSK-3\u03b2 inhibitors","volume":"21","author":"Gentile","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119071_bib17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jmb.2003.08.031","article-title":"Structural characterization of the GSK-3\u03b2 active site using selective and non-selective ATP-mimetic inhibitors","volume":"333","author":"Bertrand","year":"2003","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.119071_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1021\/ml300348c","article-title":"Azaindole-Based inhibitors of Cdc7 kinase: impact of the Pre-DFG residue, val 195","volume":"4","author":"Tong","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119071_bib19","doi-asserted-by":"crossref","first-page":"9601","DOI":"10.1002\/anie.201603797","article-title":"Discovery of a highly selective glycogen synthase Kinase-3 Inhibitor (PF-04802367) that modulates tau phosphorylation in the brain: translation for PET neuroimaging","volume":"55","author":"Liang","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119071_bib20","doi-asserted-by":"crossref","first-page":"9107","DOI":"10.1021\/jm201724m","article-title":"Discovery of novel potent and highly selective glycogen synthase Kinase-3\u03b2 (GSK3\u03b2) inhibitors for alzheimer's disease: design, synthesis, and characterization of pyrazines","volume":"55","author":"Berg","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119071_bib21","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1021\/jm901443h","article-title":"Through the \"gatekeeper door\": exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119071_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117406","article-title":"Glycogen synthase kinase-3: a potential target for diabetes","volume":"92","author":"Teli","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119071_bib23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ardp.201000028","article-title":"Proteus in the world of proteins: conformational changes in protein kinases","volume":"343","author":"Rabiller","year":"2010","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ejmech.2026.119071_bib24","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/cb500129t","article-title":"Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery?","volume":"9","author":"Zhao","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119071_bib25","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1021\/acs.jmedchem.0c01568","article-title":"Structure-Based design of potent selective Nanomolar Type-II inhibitors of Glycogen synthase Kinase-3beta","volume":"64","author":"Davies","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119071_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129932","article-title":"Design, synthesis and biological evaluation of thieno[3,2-c]pyrazol-urea derivatives as potent glycogen synthase kinase 3\u03b2 inhibitors based on the DFG-out conformation","volume":"112","author":"Yan","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119071_bib27","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1021\/cb300128b","article-title":"Targeting GSK3 from Ustilago maydis: type-II kinase inhibitors as potential antifungals","volume":"7","author":"Grutter","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119071_bib28","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.cell.2026.03.016","article-title":"Targeting angiogenesis: lessons from 25 years of normalizing tumor vasculature","volume":"189","author":"Subudhi","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119071_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107723","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2025 update","volume":"216","author":"Roskoski","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.119071_bib30","doi-asserted-by":"crossref","first-page":"33384","DOI":"10.1039\/D4RA05244G","article-title":"Recent updates on potential of VEGFR-2 small-molecule inhibitors as anticancer agents","volume":"14","author":"Chaudhari","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.119071_bib31","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1080\/07391102.2021.1872417","article-title":"Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: binding site analysis of type II, \u2018DFG-out\u2019 inhibitors","volume":"40","author":"Modi","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejmech.2026.119071_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106425","article-title":"Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy","volume":"133","author":"Liu","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119071_bib33","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/archoto.2009.14","article-title":"The effect of combination anti\u2013endothelial growth factor receptor and anti\u2013vascular endothelial growth factor receptor 2 targeted therapy on lymph node metastasis: a Study in an orthotopic nude mouse model of squamous cell carcinoma of the oral tongue","volume":"135","author":"Sano","year":"2009","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.ejmech.2026.119071_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-026-04327-4","article-title":"Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial","author":"Mahalingam","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.119071_bib35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1139\/bcb-2016-0132","article-title":"Anti-angiogenic effect of chebulagic acid involves inhibition of the VEGFR2- and GSK-3\u03b2-dependent signaling pathways","volume":"95","author":"Athira","year":"2017","journal-title":"Biochem. Cell. Biol."},{"key":"10.1016\/j.ejmech.2026.119071_bib36","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1074\/jbc.M705343200","article-title":"GSK-3\u03b2 inhibition enhances sorafenib-induced apoptosis in Melanoma cell lines","volume":"283","author":"Panka","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119071_bib37","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bbrc.2012.05.147","article-title":"GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC)","volume":"423","author":"Kawazoe","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2026.119071_bib38","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119071_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2019.100009","article-title":"Vascular Endothelial Growth Factor Receptor (VEGFR-2)\/KDR inhibitors: medicinal chemistry perspective","volume":"2","author":"Modi","year":"2019","journal-title":"Med. Drug Discovery"},{"key":"10.1016\/j.ejmech.2026.119071_bib40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1021\/ml500394m","article-title":"Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization","volume":"6","author":"Okamoto","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119071_bib41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejmech.2019.02.001","article-title":"Synthesis and evaluation of novel GSK-3beta inhibitors as multifunctional agents against Alzheimer's disease","volume":"167","author":"Shi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119071_bib42","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/13543776.2020.1815706","article-title":"Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2016\u20132019)","volume":"30","author":"Roca","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.119071_bib43","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12272-025-01545-1","article-title":"Targeting vascular endothelial growth receptor-2 (VEGFR-2): structural biology, functional insights, and therapeutic resistance","volume":"48","author":"Shah","year":"2025","journal-title":"Arch. Pharmacal Res."},{"key":"10.1016\/j.ejmech.2026.119071_bib44","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s12032-025-03086-5","article-title":"Harnessing GSK-3\u03b2 inhibition for lung cancer therapy: emerging opportunities and challenges","volume":"42","author":"Hassanein","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ejmech.2026.119071_bib45","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1021\/acs.jmedchem.0c02118","article-title":"Illuminating a dark kinase: Structure-Guided design, synthesis, and evaluation of a potent Nek1 inhibitor and its effects on the embryonic zebrafish pronephros","volume":"65","author":"Baumann","year":"2022","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:19:33Z","timestamp":1783923573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426005167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":45,"alternative-id":["S0223523426005167"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119071","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of potent Type-II GSK-3\u03b2\/VEGFR2 inhibitors with promising potential against tongue squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119071"}}